Navigation Links
Icahn School of Medicine at Mount Sinai named to new NIH Stroke Research Network
Date:12/20/2013

NEW YORK, NY Dec. 20, 2013 -The Icahn School of Medicine at Mount Sinai joins a top-flight network of 25 regional stroke centers announced by the National Institute of Health that will focus on prevention, treatment, and recovery from stroke. As part of the NIH Stroke Trials Network (NIHStrokeNet), the medical school will receive a 5-year, $1.3 million grant to build a collaborative research infrastructure for a regional coordinating stroke center.

"As conceived by the National Institute of Neurological Disorders and Stroke (NINDS), the network is intended to improve the efficiency with which we perform clinical trials in stroke," said Stanley Tuhrim, MD, one of principal investigators of the inaugural NYC Collaborative Stroke Center and Director of the Mount Sinai Stroke Center. "The goal of our effort is to pull together several major medical institutions in the City [Mount Sinai Health System, and several hospitals affiliated with Albert Einstein College of Medicine , and NYU School of Medicine] to perform clinical trials and develop and test ways of improving acute stroke treatment, prevention and rehabilitation he added. "We hope to be able to get trials done more expeditiously." To that end, the New York City Collaborative Regional Coordinating Center (NYCCRCC) will work with sister programs across the nation, the National Coordinating Center at the University of Cincinnati, and NINDS .

The National Institute of Neurological Disorders and Stroke will fund and manage the stroke network. NINDS has spearheaded advances in stroke prevention, treatment, and recovery.

The NYCC-RCC research team, working with the extended stroke community, will propose and conduct stroke protocols to be administered within the network and also train the next generation of clinical researchers in stroke. The network concept emerged from an NINDS planning effort in which stroke experts were asked what they viewed as most i
'/>"/>

Contact: Laura Newman
laura.newman@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Icahn School of Medicine at Mount Sinai awarded $2.7 million from NIH to investigate novel therapy for eczema
2. Four Researchers from Icahn School of Medicine at Mount Sinai Among the 400 Most Highly Influential Biomedical Researchers in the World
3. A Best Manuscript Award goes to Icahn School of Medicine at Mount Sinai
4. A Best Manuscript Award Goes to the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai
5. Janina A. Longtine, MD of the Icahn School of Medicine at Mount Sinai Elected President of the Association for Molecular Pathology
6. World-Renowned Gastroenterologist Jean-Frédéric Colombel, MD, Joins the Icahn School of Medicine at Mount Sinai
7. Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles
8. Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration
9. Icahn School of Medicine at Mount Sinai and Bene Pharmachem Gmbh to Collaborate on Clinical Studies for Mucopolysaccaridoses
10. Icahn School of Medicine at Mount Sinai Honors Innovators in Scientific Research and Health Care Philanthropy at 2013 Commencement Ceremony
11. Acting U.S. Surgeon General “Gets Real” with High School and College Students About Pressing Health Concerns and the Role of Humor in Wellbeing, on EICnetwork.tv
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
(Date:4/17/2014)... to a study published today in PLOS Pathogens ... where malaria is common can mount an immune response ... to avoid repeated bouts of high fever and illness ... their bloodstream. The findings may help researchers develop future ... the malaria parasite. , Each year, approximately 200 million ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... It,s estimated that as many as 10 million older ... of loneliness and isolation. , However, new research ... retired older Americans for six years found that ... of depression by more than 30 percent. , "That,s ... State University professor of telecommunication, information studies and media ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2
... ... editor of Megaregions: Planning for Global Competitiveness and director of the Center for Quality ... special meeting at The White House Clean Energy Economy Forum: Livability and Sustainable Communities ... ...
... ... ... ... , ...
... dose of vitamin D may just be what Chicagoans need ... Loyola University Chicago Marcella Niehoff School of Nursing (MNSON). This ... short and more time is spent indoors. "Vitamin D ... reported health benefits," said Sue Penckofer, PhD, RN, professor, MNSON. ...
... ... , ... , , ... HOUSTON , ...
... ... ... ... ...
... ... ... , ... , , ...
Cached Medicine News:Health News:Dr. Catherine Ross to Participate Today in White House Clean Energy Economy Forum 2Health News:Dr. Catherine Ross to Participate Today in White House Clean Energy Economy Forum 3Health News:America's Prostate Cancer Organizations Offer Pointers to House Committee on Oversight and Government Reform 2Health News:America's Prostate Cancer Organizations Offer Pointers to House Committee on Oversight and Government Reform 3Health News:America's Prostate Cancer Organizations Offer Pointers to House Committee on Oversight and Government Reform 4Health News:Vitamin D lifts mood during cold weather months 2Health News:Northstar Healthcare Inc. (TSX: NHC) Management Forecasts a Loss of $1.2 Million for 2010 at its Palladium for Surgery - Houston, Ltd. Centre 2Health News:The First Annual CQ HealthBeat Conference 2Health News:The First Annual CQ HealthBeat Conference 3Health News:The First Annual CQ HealthBeat Conference 4Health News:The First Annual CQ HealthBeat Conference 5Health News:AUA Foundation Responds to American Cancer Society Guideline for the Early Detection of Prostate Cancer 2Health News:AUA Foundation Responds to American Cancer Society Guideline for the Early Detection of Prostate Cancer 3
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)... an unprecedented effort to curb the spread of "superbugs" such as ... an advanced and portable UV germicidal lamp manufactured by MRSA-UV is ... In order to prevent EMS paramedics and transport patients ... Palm Beach Fire Rescue is the first in the ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... Combination Clinical Trials ... SOUTH SAN FRANCISCO, Calif., June 16 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... the company,s lead drug candidate, voreloxin (formerly,SNS-595), including updated results ... single agent in relapsed or refractory patients with acute,myeloid leukemia ...
... Requip XL Improved Symptoms in Patients Not Optimally ... "Off" Time by Nearly Two Hours Per Day, ... (NYSE: GSK ) today announced the approval ... for the treatment,of the signs and symptoms of ...
Cached Medicine Technology:Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 2Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 3Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 4Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 5Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 6U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 2U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 3U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 4U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: